Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
NYSE COMPOSITE INDX
Gold
Crude Oil
ATARA BIOTHERAPE RG
(NQ:
ATRA
)
39.20
USD
UNCHANGED
Official Closing Price
/ Updated:
8:00 PM EDT, Jul 20, 2018
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
228,419
Open
39.35
Bid (Size)
36.00 (100)
Ask (Size)
40.85 (500)
Prev. Close
39.20
Today's Range
38.65 - 39.83
52wk Range
12.65 - 54.45
Shares Outstanding
43,949,486
Dividend Yield
N/A
Performance
YTD
+116.57%
+116.57%
1 Month
-7.22%
-7.22%
3 Month
-2.37%
-2.37%
6 Month
+17.54%
+17.54%
1 Year
+133.33%
+133.33%
Top News
More News
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
June 25, 2018
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
Read More
from
GlobeNewswire News Releases
Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
June 15, 2018
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
Read More
from
GlobeNewswire News Releases
More News
Read More
Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)
June 13, 2018
from
GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2018
from
GlobeNewswire News Releases
Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer
June 07, 2018
from
GlobeNewswire News Releases
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
May 29, 2018
from
GlobeNewswire News Releases
New Research Coverage Highlights Seaboard, The Hanover Insurance Group, Atara Biotherapeutics, Plexus, NV5 Global, and Analogic — Consolidated Revenues, Company Growth, and Expectations for 2018
May 29, 2018
from
GlobeNewswire News Releases
Biotech Market Value Set to Grow Due to Technological Advancements
May 21, 2018
from
PR Newswire
Analysts Forecast 10% Gains Ahead For JKJ
June 28, 2018
category
ETFs
from
ETF Channel
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Associat
May 17, 2018
from
GlobeNewswire News Releases
First Week of August 17th Options Trading For Atara Biotherapeutics (ATRA)
June 22, 2018
category
Stocks
from
Market News Video
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
